Gan & Lee Pharmaceuticals (603087.SH): First subject dosed in Phase I clinical trial of GLR1075 injection

Zhitong Finance APP News, Gan & Lee Pharmaceuticals (603087.SH) announced that the company's self-developed GLR1075 Injection is undergoing Phase I clinical trials in China, and the first subject dosing was successfully completed recently.